This site is only for UK healthcare professionals and contains promotional information.
Prescribing Information can be found at the bottom of this page.

Our products

ILUMETRI®
(tildrakizumab)

The IL-23 with up to 5 years of proven psoriasis control in adults, reinforced by real-world experience1–4

Skilarence®
(dimethyl fumarate)

Help adult patients with moderate-to-severe plaque psoriasis achieve balance with their systemic therapy

KLISYRI®
(tirbanibulin ointment)

Discover a new treatment experience focused on the needs of adult patients with actinic keratosis

Join us at these dermatology events

DermaExchange

Stay up to date with developments in dermatology

PM Academy webinars

Join our webinars on protecting patients, optimising
healthcare and maximising budgets

Resources for your practice

Almirall tools

Streamline your local biologic treatment pathways

Almirall resources

Explore resources for your practice and patients

Strength for actinic keratosis, tolerability for patients5,6

Learn more about KLISYRI®

Skilarence®: meet the patients

Meet the broad range of patients with psoriasis suitable for treatment with Skilarence®

Join our community

Register with Almirallmed to stay updated on the latest dermatology events, product information and other valuable resources.

References 

  1. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866. 
  2. Tsianakas A, et al. Interim analysis of the non-interventional study TILOT: effectiveness of tildrakizumab in long-term treatment of moderate to severe plaque psoriasis in routine practice. EADV Congress. 29–31 October 2020. Poster: P1336. 
  3. Drerup K, et al. Real world data from a large prospective cohort study (KTC) using tildrakizumab in psoriasis. EADV Congress. 29–31 October 2020. Poster: P1294. 
  4. Burlando M, et al. Drugs Context 2021;10:2–6.
  5. KLISYRI® PI. KLISYRI® SmPC. Almirall.
  6. Blauvelt A, et al. Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520.
My Favorites